Clinical trials exploring the cardiovascular and renal outcomes of GLP-1RA and sodium-glucose cotransporter-2 inhibitors (SGLT2i) not only change the treatment paradigm of diabetes but also support a more holistic approach beyond glycemic control which emphasize on cardiac and reno-protective effects (36). Here, SLC5A2 is linked to diabetes mellitus.